| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | 28.57% | HC Wainwright & Co. | $2 → $4.5 | Maintains | Buy |
| 05/13/2022 | — | Lake Street | Downgrades | Buy → Hold | |
| 03/08/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 01/18/2022 | -42.86% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 08/28/2020 | 71.43% | Lake Street | → $6 | Initiates Coverage On | → Buy |
| 08/25/2020 | 42.86% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
Brickell Biotech Questions & Answers
The latest price target for Brickell Biotech (NASDAQ: BBI) was reported by HC Wainwright & Co. on August 16, 2022. The analyst firm set a price target for $4.50 expecting BBI to rise to within 12 months (a possible 28.57% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Brickell Biotech (NASDAQ: BBI) was provided by HC Wainwright & Co., and Brickell Biotech maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Brickell Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Brickell Biotech was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
While ratings are subjective and will change, the latest Brickell Biotech (BBI) rating was a maintained with a price target of $2.00 to $4.50. The current price Brickell Biotech (BBI) is trading at is $3.50, which is within the analyst's predicted range.